Medications

Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.

Fatigue affects a large share of people with IBD and often persists despite remission; understanding treatment options and the need for a broad care plan can help patients and clinicians set realistic goals and...

Company-reported one-year results suggest mirikizumab (Omvoh), an IL-23p19 inhibitor, can achieve multi-dimensional treatment goals including symptom control, quality-of-life improvement, and steroid-free deep remission...

Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...

An oral IL-23 blocker showed benefit in a Phase IIb trial for moderate-to-severe ulcerative colitis, which could add a new pill option for patients—especially those who’ve failed injectable biologics.

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Mirikizumab, IL-23 inhibitor, and Research and clinical trials. Open the original article for the full...

Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Mirikizumab, and IL-23 inhibitor. Open the original article for the full details.

Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...

New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.

These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...

A phase 2 trial testing an oral integrin α4β7 inhibitor could matter because it explores a potential new mechanism for treating moderately to severely active ulcerative colitis, including patients who have failed other...

Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...

The paper reports novel ibuprofen-derived compounds that reduce inflammation and restore intestinal immune balance in preclinical models of ulcerative colitis, suggesting a potential new drug-development direction that...

If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...

Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to...

Late-stage (Phase 3) AFFIRM data for subcutaneous Skyrizi in Crohn’s disease are being presented publicly — that could lead to new treatment options if regulators approve expanded indications, and it influences...

Intestinal fibrosis can cause strictures and obstructive complications that often lead to surgery. Research identifying the cellular drivers and druggable pathways could guide development of treatments to prevent or slow...

Positive phase 3 results for a subcutaneous risankizumab induction regimen may expand access to an IL‑23 p19 therapy option that avoids IV induction and showed strong short-term remission and endoscopic response rates in...

Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...

This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...

Positive Phase 3 data for a subcutaneous formulation of risankizumab (SKYRIZI) in Crohn’s disease could expand treatment options for people with moderate-to-severe Crohn’s and influence prescribing and insurance coverage...

This registry study offers real-world data on ozanimod effectiveness, persistence, and safety in UC patients, which can help patients and clinicians set expectations beyond clinical trial settings.

Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...

A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.

Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...

The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...

The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...

New Phase 3 data suggest subcutaneous risankizumab (Skyrizi) can achieve meaningful endoscopic remission and ulcer-free endoscopy rates in adults with active Crohn's disease, including higher responses in patients...

Endoscopic remission (visual healing) is linked to better long-term outcomes in Crohn's disease. An approved subcutaneous induction option could make risankizumab easier to use outside infusion settings.

The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.

This trial focuses on fibrostenosing Crohn’s disease, a form of IBD where strictures can block the intestine; a successful drug could offer a medical option to improve endoscopic passability and reduce need for...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.

This advances a drug candidate (ontunisertib) aimed specifically at fibrostenosing Crohn’s disease — a form of IBD where strictures can block the bowel and endoscopic passability is a meaningful clinical measure.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Celiac Disease, and Medications. The original article is from British medical journal.

A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...

New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.

Cure8 found this source from marketwatch.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.

Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis and Medications. The original article is from British medical journal (Clinical research ed.).

Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from British medical journal (Clinical...

Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...

This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...

This trial tests whether adding the oral antibiotic nifuroxazide to standard mesalamine improves quality of life for people with mild-to-moderate ulcerative colitis. Results, if published, could suggest a new adjunctive...

Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Upadacitinib, and Tofacitinib.

Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from seekingalpha.com.